SARS-CoV-2 Antiviral Therapy

@article{Tao2021SARSCoV2AT,
  title={SARS-CoV-2 Antiviral Therapy},
  author={Kaiming Tao and Philip L. Tzou and Janin Nouhin and Hector F. Bonilla and Prasanna Jagannathan and Robert W. Shafer},
  journal={Clinical Microbiology Reviews},
  year={2021},
  volume={34}
}
The development of effective antiviral therapy for COVID-19 is critical for those awaiting vaccination, as well as for those who do not respond robustly to vaccination. This review summarizes 1 year of progress in the race to develop antiviral therapies for COVID-19, including research spanning preclinical and clinical drug development efforts, with an emphasis on antiviral compounds that are in clinical development or that are high priorities for clinical development. SUMMARY The development… 

Druggable targets and therapeutic development for COVID-19

The potential medicinal value of essential proteins of SARS-CoV-2 and key host factors are discussed, and the most updated therapeutic interventions for COVID-19 patients are summarized.

Antivirals for Coexistence with COVID-19: Brief Review for General Physicians

Although the severe acute respiratory syndrome coronavirus 2 will not be completely eradicated, if the use of antiviral drugs is established, the COVID-19 pandemic will end through coexistence with the virus.

Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants

This review summarized the molecular characteristics, immune evasion, and impacts of the SARS-CoV-2 variants and focused on the parallel comparison of different variants in mutational profile, transmissibility and tropism alteration, treatment effectiveness, and clinical manifestations, in order to provide a comprehensive landscape for SARs-Cov-2 variant research.

Modulating Fingolimod (FTY720) Anti-SARS-CoV-2 Activity Using a PLGA-Based Drug Delivery System

The combination of drug repurposing and nanotechnology as NP@FTY720 is presented for the first time and represents a promising frontline in the fight against COVID-19.

COVID-19 Pneumonia in Vaccinated Population: A Six Clinical and Radiological Case Series

It is suggested that in fully vaccinated people, caution should be preserved, and the use of masks and social distancing should be continued in all closed environments to better understand how various factors can influence vaccine immunogenicity as the presence of virus mutations, age factors, andThe presence of an immunocompromised state.

Potential drug discovery for COVID-19 treatment targeting Cathepsin L using a deep learning-based strategy

Association between inflammatory cytokines and anti-SARS-CoV-2 antibodies in hospitalized patients with COVID-19

Early responses of elevated cytokines such as IL-6 reflect the active immune responses, leading to high titers of IgG antibodies against COVID-19, especially in severely ill older patients.

Cotton flower metabolites inhibit SARS‐CoV‐2 main protease

Several CF natural products, including astragalin, myricitrin, and astilbin, significantly inhibited Mpro with half‐maximal inhibitory concentrations (IC50s) of 0.13, 10.73, and 7.92 μm, respectively.

Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2

The development of effective antiviral drugs against SARS-CoV-2 is urgently needed and a global health priority. In light of the initial data regarding the repurposing of hydroxychloroquine (HCQ) to

References

SHOWING 1-10 OF 403 REFERENCES

Neutralizing monoclonal antibodies for treatment of COVID-19

The precedent for passive immunization and lessons learned from using antibody therapies for viral infections such as respiratory syncytial virus, Ebola virus and SARS-CoV infections are reviewed and a need to understand factors such as the kinetics of viral load and its correlation with clinical outcomes is understood.

Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets

All antiviral drugs tested marginally reduced the overall clinical scores of infected ferrets but did not significantly affect in vivo virus titers.

Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2

Five of the newly identified drugs had a safety index (cytotoxic/effective concentration) of >600, indicating wide therapeutic window compared to hydroxychloroquine which had safety index of 22 in similar experiments, and Mechanistically, five of the effective compounds were found to block SARS-CoV-2 S protein-mediated cell fusion.

SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model

32 new bicycloproline-containing Mpro inhibitors derived from either boceprevir or telaprevir, both of which are approved antivirals are designed and synthesized and display excellent antiviral activity both in vitro and in a transgenic mouse model.

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Two peptidomimetic aldehydes were designed, synthesized, and evaluated as antiviral drug candidates, and both exhibited excellent inhibitory activity and potent anti-SARS-CoV-2 infection activity.

Lack of antiviral activity of darunavir against SARS-CoV-2

Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection

The pharmacokinetic characteristics of favipiravir and possible drug–drug interactions from the view of drug metabolism are summarized in the hope this will be helpful for the design of clinical trials for favipIRavir in COVID‐2019.

REGEN-COV protects against viral escape in preclinical and human studies

This study demonstrates that a combination of non-competing antibodies, REGEN-COV, not only provides full coverage against current variants of concern/interest but also protects against emergence of new such variants and their potential seeding into the population in a clinical setting.

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A

The results indicate that plitidepsin is a promising therapeutic candidate for COVID-19, and in cells, the drug is substantially more potent than remdesivir against SARS-CoV-2, with limited cellular toxicity.

A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CLpro Inhibitor PF-00835231 as a Potential New Treatment for COVID-19

In vitro evidence is provided for the potential of PF-00835231 as an effective SARS-CoV-2 antiviral and addresses concerns that emerged based on prior studies in nonhuman in vitro models.
...